NVYTF:OTCMKTS
Novacyt SA
$0.57
0.00%
(0.00) 1D
Aug 21, 9:30:11 AM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVYTF...
Mkt. cap
34.84M
Avg. vol.
28.00
Volume
0.00
52-wk high
$0.57
52-wk low
$0.48
Beta
2.10
Shares outstanding
72.59M
No. of employees
216
Mkt. cap
34.84M
Avg. vol.
28.00
Volume
0.00
52-wk high
$0.57
52-wk low
$0.48
Beta
2.10
Shares outstanding
72.59M
No. of employees
216
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA